Výsledky vyhledávání - "Rivka Katzenelson"

Akademický článek

1229 Pre-treatment plasma proteomics-based predictive biomarkers for immune related adverse events in non-small cell lung cancer

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)

Externí odkaz: https://doaj.org/article/0e3e42ead80141f4b5b96a3923da8e1d

Zobrazit plný text záznamu

A novel decision-making tool for first-line treatment selection in metastatic non-small cell lung cancer based on plasma proteome profiling

ImportanceAdvanced stage non-small cell lung cancer (NSCLC) patients with no driver mutations are typically treated with immune checkpoint inhibitor (ICI)-based therapy, either in the form of monotherapy or concurrently with chemotherapy, while treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ae81768a379fb89e842974009b951303
https://doi.org/10.1101/2022.12.01.22282769

Zobrazit plný text záznamu

136 A plasma proteomic based predictive biomarker for response to immunotherapy in NSCLC

Autor: Michal Harel, Coren Lahav, Ido Wolf, Ella Tepper, Maya Gottfried, Raya Leibowitz, Mahmoud Abu-Amna, Abed Agbarya, Rivka Katzenelson, Michal Lotem, Mor Moskovitz, Alona Zer, Ina Koch, Niels Reinmuth, Adam Dicker, David Gandara, Petros Christopoulos, David Carbone

Publikováno v: Regular and Young Investigator Award Abstracts.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8ddb7ee0308478271dcd31c0bab19cf9
https://doi.org/10.1136/jitc-2022-sitc2022.0136

Zobrazit plný text záznamu

Abstract 2159: A pretreatment blood-based proteomic biomarker for enhanced decision-making in non-small cell lung cancer

Publikováno v: Cancer Research. 83:2159-2159

Introduction: Treatment modality selection for metastatic NSCLC patients (immunotherapy alone vs. combination of immunotherapy with chemotherapy) relies mainly on determining the programmed cell death 1 (PD-L1) expression levels in the tumor. However

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7a5bb145575cf4c0f99987d80f4dfe67
https://doi.org/10.1158/1538-7445.am2023-2159

Zobrazit plný text záznamu

Personalized approach for response prediction and treatment management for non-small cell lung cancer patients based on a liquid biopsy

Publikováno v: Journal of Clinical Oncology. 40:e21132-e21132

e21132 Background: To date, predicting response to immune checkpoint blockade (ICB) therapy in non-small cell lung cancer (NSCLC) patients is based on assessing PD-L1 levels in tumor biopsies. However, such assays are only moderately predictive. In a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e8653108dff87cdb9f83fe50fdf550a3
https://doi.org/10.1200/jco.2022.40.16_suppl.e21132

Zobrazit plný text záznamu

74P A predictive signature for response to immunotherapy in non-small cell lung cancer based on plasma proteomics and clinical parameters

Autor: Michal Harel, Yehonatan Elon, Hovav Nechushtan, Jair Bar, Itamar Sela, Alona Zer, Yuval Shaked, Maya Gottfried, M. Abu-Amana, Adam P. Dicker, Ofer Sharon, Rivka Katzenelson, Ido Wolf, Iris Kamer, Eyal Jacob, Abed Agbarya, Coren Lahav, Galit Yahalom, M.T. Moskovits

Publikováno v: Annals of Oncology. 32:S388

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f94be3c5e7cd99a5b41f365af05ca5e5
https://doi.org/10.1016/j.annonc.2021.08.354

Zobrazit plný text záznamu

Integration of proteomic and clinical data for the prediction of response to immune checkpoint inhibitor therapy in non-small cell lung cancer

Publikováno v: Journal of Clinical Oncology. 39:e21110-e21110

e21110 Background: Immune checkpoint inhibitor (ICI) therapy represents one of the most promising cancer treatments to date. However, despite unprecedented rates of durable response, only a small proportion of patients benefits from this approach. Ma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dae720b3e0fa5feda977bfbf489d2af3
https://doi.org/10.1200/jco.2021.39.15_suppl.e21110

Zobrazit plný text záznamu

Are all RET fusions NSCLC alike? Clinical pitfalls and response to targeted therapy: KIF5B vs. CCDC6

Autor: Nir Peled, Victoria Neiman, Michal Sarfaty, Maya Ilouze, Addie Dvir, Maya Gottfried, Lior Soussan-Gutman, Mira Wollner, Rivka Katzenelson, Hovav Nechushtan, Assaf Moore

Publikováno v: Journal of Clinical Oncology. 33:e19005-e19005

e19005 Background: Rearranged during Transfection (RET) fusions have been reported in 1-2% of lung adenocarcinomas (LADC), KIF5B-RET fusion being the common variant, and less commonly CCDC6-RET, TR...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cba1a0bf6a36f02115cba9054ce8c2ec
https://doi.org/10.1200/jco.2015.33.15_suppl.e19005

Zobrazit plný text záznamu

Landscape of genomic alterations (GA) detected by next-generation sequencing (NGS) in non-small cell lung cancer (NSCLC) adenocarcinoma in Israel

Autor: Nir Peled, Dov Flex, Kai Wang, Alona Zer, Amir Onn, Moshe Mishaeli, Abed Agbarya, Phil Stephens, Vincent A. Miller, Lior Soussan-Gutman, Mira Wollner, Jeffrey S. Ross, Amiel Segal, Hovav Nechushtan, Rivka Katzenelson, Julia Dudnik, Jair Bar, Maya Gottfried, Addie Dvir

Publikováno v: Journal of Clinical Oncology. 32:e19111-e19111

e19111 Background: Profiling lung cancer tumors for targetable GAs is the cornerstone for individualizing treatment for this disease. We hypothesized that NSCLC samples would be enriched in actiona...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::28fca75c1ff953d32fed903fdb64b6b7
https://doi.org/10.1200/jco.2014.32.15_suppl.e19111

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání